CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05383196
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:27.502085+00:00
- Published At
- 2026-02-11T00:00:00+00:00
- Record Updated At
- 2026-02-11
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Breast Cancer", "Invasive Breast Cancer", "Unresectable Breast Carcinoma", "Locally Advanced Breast Cancer", "Metastatic Breast Cancer", "Inflammatory Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-11"- protocolSection.identificationModule.nctId
"NCT05383196"- protocolSection.identificationModule.officialTitle
"A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.